<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00869518</url>
  </required_header>
  <id_info>
    <org_study_id>08033578</org_study_id>
    <nct_id>NCT00869518</nct_id>
  </id_info>
  <brief_title>Rifabutin Based Therapy for the Eradication of Staphylococcus Aureus Colonization in HIV Infected Adults</brief_title>
  <official_title>Randomized, Double-Blinded Evaluation of Rifabutin Based Therapy for Eradication of Staphylococcus Aureus Carriage in HIV Infected Individuals With Prior Skin and Skin Structure Infections</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      DESIGN: This single center, double-blinded, randomized phase II study is being conducted to
      assess the efficacy of a rifabutin based regimen to eliminate S. aureus colonization in HIV
      infected individuals. Individuals must have HIV infection and a skin and skin structure
      infection (SSSI) in the prior 6 months to be eligible for screening. Prior to enrollment,
      subjects will be cultured for evidence of S. aureus colonization. Individuals who are culture
      positive at ≥ one body site will be eligible for enrollment. Subjects who meet inclusion and
      exclusion criteria and consent to participate in the study will be randomized to seven days
      of rifabutin plus trimethoprim-sulfamethoxazole (TMP-SMX) or TMP-SMX alone. Following
      completion of treatment subjects will be screened seven days, 30 days, and 60 days
      post-treatment for colonization at multiple body-sites. Subjects will also be actively
      followed for evidence of SSSI.

      SUBJECT PARTICIPATION DURATION: 12 weeks

      SAMPLE SIZE: 88 total subjects

      POPULATION: 200 HIV infected individuals who receive care at San Francisco General Hospital
      HIV clinic (Ward 86) with a history of SSSI in the prior 6 months will be screened for S.
      aureus colonization.

      DESCRIPTION OF AGENT OR INTERVENTION: This is a double-blind trial comparing rifabutin plus
      TMP-SMX versus placebo plus TMP-SMX. Placebo will be administered at a dose of 300 mg p.o.
      daily or an equivalent dose depending on co-administration of other drugs that may adjust the
      serum level of rifabutin. TMP-SMX will be administered at a dose of trimethoprim 160 mg and
      sulfamethoxazole 800 mg p.o. twice daily or adjusted per CrCl. Study drug will be provided by
      the study and administered for 7 days.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Poor enrollment
  </why_stopped>
  <start_date>July 2009</start_date>
  <completion_date type="Actual">December 2010</completion_date>
  <primary_completion_date type="Actual">December 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Eradication of S. Aureus Colonization</measure>
    <time_frame>30 days following completion of treatment</time_frame>
    <description>Eradication was measured by performing cultures for S aureus at the nose, throat, and groin</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Eradication of S. Aureus Colonization</measure>
    <time_frame>7 days following completion of treatment</time_frame>
    <description>Eradication was measured by performing cultures for S aureus at the nose, throat, and groin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Eradication of S. Aureus Colonization</measure>
    <time_frame>60 days following completion of treatment</time_frame>
    <description>Eradication was measured by performing cultures for S aureus at the nose, throat, and groin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Recurrent Skin and Skin Structure Infections (SSTI)</measure>
    <time_frame>up to 30 days following completion of treatment</time_frame>
    <description>recurrent SSTI was by self-report and exam, followed until positive colonization</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Staphylococcus Aureus</condition>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>Rifabutin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Subjects will be assigned to 7 days of treatment with rifabutin plus trimethoprim-sulfamethoxazole</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Subjects will be assigned to 7 days of treatment with placebo plus trimethoprim-sulfamethoxazole</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>rifabutin plus trimethoprim sulfamethoxazole</intervention_name>
    <description>rifabutin 300 mg PO daily or equivalent depending on concomitant medications plus trimethoprim-sulfamethoxazole 1 DS tab twice daily both for 7 days</description>
    <arm_group_label>Rifabutin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo plus trimethoprim-sulfamethoxazole</intervention_name>
    <description>placebo plus trimethoprim-sulfamethoxazole 1 DS tab twice daily both for 7 days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age &gt; 18 years

          2. HIV infection as reported by the subject's physician

          3. Physician-reported SSSI within the prior 6 months.

          4. S. aureus colonization at ≥ 1 body site as defined as a positive culture for S. aureus
             at minimum one of five cultures taken at pre-enrollment screening.

          5. Subjects (or their legally acceptable representatives) must have signed an informed
             consent documentation indicating that they understand the purpose of and procedures
             required for the study, and are willing to participate in the study

        Exclusion Criteria:

          1. Female subjects who are pregnant or lactating.

          2. Known or suspected hypersensitivity to rifabutin, a rifamycin class antimicrobial,
             TMP-SMX or another sulfa based medication.

          3. Known or suspected condition or concurrent treatment that would be contraindicated by
             the prescribing of rifabutin or TMP-SMX.

          4. Receipt of an anti-staphylococcal antimicrobial within 14 days prior to administration
             of study drug (TMP-SMX, clindamycin, any macrolide, any tetracycline, any rifamycin,
             any fluoroquinolone, vancomycin, linezolid, daptomycin, any penicillin, any
             carbapenem, or any cephalosporin).

          5. Diagnosis of an active SSSI or other signs and symptoms of S. aureus infection at the
             time of study enrollment

          6. Physician-reported diagnosis of active or untreated latent mycobacterial infection

          7. CrCl &lt; 30 ml/min as determined by the Cockcroft-Gault Method using a serum creatinine
             from a value obtained within the last 6 months.

          8. No serum creatinine value available for the subject in the SFGH clinical laboratory
             system (LCR) within 6 months prior to enrollment.

          9. Physician-reported diagnosis of end-stage liver disease

         10. Physician-reported diagnosis of uveitis in the past or at time of enrollment

         11. Concomitant use of medications with unknown pharmacokinetic interactions with
             rifabutin or contraindicated with rifabutin (unboosted indinavir, unboosted
             saquinavir, delavirdine, atovaquone, azithromycin, Bacillus of Calmette and Guerin
             [only if recent administration for bladder cancer treatment], dapsone, dasatinib,
             erlotininb, ethinyl estradiol, fluconazole, imatinab, itinotecan, itraconazole,
             ixabepilone, lapatinib, levonorgestrel, mestranol, nilotininb, norelgestromin,
             norethindrone, posaconazole, ranolazine, sirolimus, sunitinib, tacrolimus,
             temsirolimus, trimetrexate, voriconazole, warfarin)

         12. Colonizing S. aureus isolate resistant to TMP-SMX

         13. Colonizing S. aureus isolate resistant to rifampin (rifampin resistance will serve as
             a surrogate for rifabutin resistance at initial screening)

         14. Subjects who are unlikely to be able to comply with the mandated study visits
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Henry F Chambers, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Califronia, San Francisco</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Brian S Schwartz, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>San Francisco General Hospital</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 24, 2009</study_first_submitted>
  <study_first_submitted_qc>March 25, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 26, 2009</study_first_posted>
  <results_first_submitted>March 13, 2014</results_first_submitted>
  <results_first_submitted_qc>March 13, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 21, 2014</results_first_posted>
  <last_update_submitted>April 23, 2014</last_update_submitted>
  <last_update_submitted_qc>April 23, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 14, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Staphylococcus aureus</keyword>
  <keyword>colonization</keyword>
  <keyword>eradication</keyword>
  <keyword>HIV</keyword>
  <keyword>rifabutin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Trimethoprim</mesh_term>
    <mesh_term>Trimethoprim, Sulfamethoxazole Drug Combination</mesh_term>
    <mesh_term>Sulfamethoxazole</mesh_term>
    <mesh_term>Rifabutin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Rifabutin</title>
          <description>Subjects assigned to 7 days of treatment with rifabutin plus trimethoprim-sulfamethoxazole
rifabutin plus trimethoprim sulfamethoxazole: rifabutin 300 mg PO daily or equivalent depending on concomitant medications plus trimethoprim-sulfamethoxazole 1 DS tab twice daily both for 7 days</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Subjects assigned to 7 days of treatment with placebo plus trimethoprim-sulfamethoxazole
placebo plus trimethoprim-sulfamethoxazole: placebo plus trimethoprim-sulfamethoxazole 1 DS tab twice daily both for 7 days</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Rifabutin</title>
          <description>Subjects assigned to 7 days of treatment with rifabutin plus trimethoprim-sulfamethoxazole
rifabutin plus trimethoprim sulfamethoxazole: rifabutin 300 mg PO daily or equivalent depending on concomitant medications plus trimethoprim-sulfamethoxazole 1 DS tab twice daily both for 7 days</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Subjects assigned to 7 days of treatment with placebo plus trimethoprim-sulfamethoxazole
placebo plus trimethoprim-sulfamethoxazole: placebo plus trimethoprim-sulfamethoxazole 1 DS tab twice daily both for 7 days</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="6"/>
            <count group_id="B3" value="12"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42.3" lower_limit="25" upper_limit="49"/>
                    <measurement group_id="B2" value="43.5" lower_limit="25" upper_limit="63"/>
                    <measurement group_id="B3" value="42.9" lower_limit="25" upper_limit="63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Eradication of S. Aureus Colonization</title>
        <description>Eradication was measured by performing cultures for S aureus at the nose, throat, and groin</description>
        <time_frame>30 days following completion of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rifabutin</title>
            <description>Subjects assigned to 7 days of treatment with rifabutin plus trimethoprim-sulfamethoxazole
rifabutin plus trimethoprim sulfamethoxazole: rifabutin 300 mg PO daily or equivalent depending on concomitant medications plus trimethoprim-sulfamethoxazole 1 DS tab twice daily both for 7 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subjects assigned to 7 days of treatment with placebo plus trimethoprim-sulfamethoxazole
placebo plus trimethoprim-sulfamethoxazole: placebo plus trimethoprim-sulfamethoxazole 1 DS tab twice daily both for 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Eradication of S. Aureus Colonization</title>
          <description>Eradication was measured by performing cultures for S aureus at the nose, throat, and groin</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Eradication of S. Aureus Colonization</title>
        <description>Eradication was measured by performing cultures for S aureus at the nose, throat, and groin</description>
        <time_frame>7 days following completion of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Rifabutin</title>
            <description>Subjects assigned to 7 days of treatment with rifabutin plus trimethoprim-sulfamethoxazole
rifabutin plus trimethoprim sulfamethoxazole: rifabutin 300 mg PO daily or equivalent depending on concomitant medications plus trimethoprim-sulfamethoxazole 1 DS tab twice daily both for 7 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subjects assigned to 7 days of treatment with placebo plus trimethoprim-sulfamethoxazole
placebo plus trimethoprim-sulfamethoxazole: placebo plus trimethoprim-sulfamethoxazole 1 DS tab twice daily both for 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Eradication of S. Aureus Colonization</title>
          <description>Eradication was measured by performing cultures for S aureus at the nose, throat, and groin</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Eradication of S. Aureus Colonization</title>
        <description>Eradication was measured by performing cultures for S aureus at the nose, throat, and groin</description>
        <time_frame>60 days following completion of treatment</time_frame>
        <population>Participants were colonized at day 30 (i.e. S. Aureus not eradicated) and were not checked again for follow-up.</population>
        <group_list>
          <group group_id="O1">
            <title>Rifabutin</title>
            <description>Subjects assigned to 7 days of treatment with rifabutin plus trimethoprim-sulfamethoxazole
rifabutin plus trimethoprim sulfamethoxazole: rifabutin 300 mg PO daily or equivalent depending on concomitant medications plus trimethoprim-sulfamethoxazole 1 DS tab twice daily both for 7 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subjects assigned to 7 days of treatment with placebo plus trimethoprim-sulfamethoxazole
placebo plus trimethoprim-sulfamethoxazole: placebo plus trimethoprim-sulfamethoxazole 1 DS tab twice daily both for 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Eradication of S. Aureus Colonization</title>
          <description>Eradication was measured by performing cultures for S aureus at the nose, throat, and groin</description>
          <population>Participants were colonized at day 30 (i.e. S. Aureus not eradicated) and were not checked again for follow-up.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Recurrent Skin and Skin Structure Infections (SSTI)</title>
        <description>recurrent SSTI was by self-report and exam, followed until positive colonization</description>
        <time_frame>up to 30 days following completion of treatment</time_frame>
        <population>participants were followed until colonization; therefore, no participants were followed past 30 days</population>
        <group_list>
          <group group_id="O1">
            <title>Rifabutin</title>
            <description>Subjects assigned to 7 days of treatment with rifabutin plus trimethoprim-sulfamethoxazole
rifabutin plus trimethoprim sulfamethoxazole: rifabutin 300 mg PO daily or equivalent depending on concomitant medications plus trimethoprim-sulfamethoxazole 1 DS tab twice daily both for 7 days</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Subjects assigned to 7 days of treatment with placebo plus trimethoprim-sulfamethoxazole
placebo plus trimethoprim-sulfamethoxazole: placebo plus trimethoprim-sulfamethoxazole 1 DS tab twice daily both for 7 days</description>
          </group>
        </group_list>
        <measure>
          <title>Recurrent Skin and Skin Structure Infections (SSTI)</title>
          <description>recurrent SSTI was by self-report and exam, followed until positive colonization</description>
          <population>participants were followed until colonization; therefore, no participants were followed past 30 days</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>30 days after treatment</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Rifabutin</title>
          <description>Subjects assigned to 7 days of treatment with rifabutin plus trimethoprim-sulfamethoxazole
rifabutin plus trimethoprim sulfamethoxazole: rifabutin 300 mg PO daily or equivalent depending on concomitant medications plus trimethoprim-sulfamethoxazole 1 DS tab twice daily both for 7 days</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Subjects assigned to 7 days of treatment with placebo plus trimethoprim-sulfamethoxazole
placebo plus trimethoprim-sulfamethoxazole: placebo plus trimethoprim-sulfamethoxazole 1 DS tab twice daily both for 7 days</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Hypersensitivity reaction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Brian S. Schwartz, MD</name_or_title>
      <organization>University of California, San Francisco</organization>
      <phone>415-476-5767</phone>
      <email>brian.schwartz@ucsf.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

